anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This includes toxicity arising from accidental intravascular injection of ZORCAINE discussed in Section 5.1, as well as that related to higher systemic concentrations of local anesthetics or epinephrine [see Warnings and Precautions (5.3)]. Systemic absorption of local anesthetics including ZORCAINE can produce effects on the central nervous and cardiovascular systems.

At blood concentrations achieved with therapeutic doses of ZORCAINE, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations of ZORCAINE can depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, possibly resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilatation occurs, leading to decreased cardiac output and arterial blood pressure. ZORCAINE should also be used with caution in patients with heart block as well as those with impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by these drugs.

Restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of central nervous system toxicity.

Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after each local anesthetic injection of ZORCAINE. Repeated doses of ZORCAINE may cause significant increases in blood levels because of possible accumulation of the drug or its metabolites. The lowest dosage that results in effective anesthesia should be used to decrease the risk of high plasma levels and serious adverse effects. Tolerance to elevated blood levels varies with the status of the patient. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Precautions for epinephrine administration, discussed in Section 5.3, should be observed.

Debilitated patients, elderly patients, acutely ill patients, and pediatric patients should be given reduced doses commensurate with their age and physical condition [see Dosage and Administration (2.1, 2.3)]. No studies have been performed in patients with liver impairment, and caution should be used in patients with severe hepatic disease.
PURPOSE:To obtain the titled active water having synergistically enhanced mineral effect, by chemically treating an ore called medicinal stone readily eluting mineral, mixing the resultant strongly acidic active water with strongly alkaline active water in a high concentration obtained from oyster or scallop shells and adjusting the pH. CONSTITUTION:An ore, e.g. quartz porphyry or quartz trachite, etc., capable of readily eluting mineral is finely powdered, dipped in a sulfuric acid solution in 25% concentration, heated and stirred to prepare an acidic solution containing the eluted mineral. On the other hand, oyster or scallop shells are fired in an electric furnace at 2,000 deg.C to give fine strong electrolytic calcium powder, which is then dissolved in water to prepare an alkaline solution. The above-mentioned acidic solution is neutralized with the alkaline solution and pH is adjusted to give the aimed mineral active water in a high concentration. The neutralization can be carried out without deteriorating the mineral and ionizing action of ths strongly acidic active water. The amount of minor elements in the sea, e.g. Ca, Mg, P, etc., lacking in igneous rock can be further increased.
Sterile neuroinflammation is a major driver of multiple neurological diseases. Myelin debris can act as an inflammatory stimulus to promote inflammation and pathologies, but the mechanism is poorly understood. Here, we showed that lysophosphatidylserine (LysoPS)-GPR34 axis played a critical role in microglia-mediated myelin debris sensing and the subsequent neuroinflammation. Myelin debris-induced microglia activation and proinflammatory cytokine expression relied on its lipid component LysoPS. Both myelin debris and LysoPS promoted microglia activation and the production of proinflammatory cytokines via GPR34 and its downstream PI3K-AKT and ERK signaling. In vivo, reducing the content of LysoPS in myelin or inhibition of GPR34 with genetic or pharmacological approaches reduced neuroinflammation and pathologies in the mouse models of multiple sclerosis and stroke. Thus, our results identify GPR34 as a key receptor to sense demyelination and CNS damage and promote neuroinflammation, and suggest it as a potential therapeutic target for demyelination-associated diseases.
Hearing disorders pose significant challenges to individuals experiencing them and their overall quality of life, emphasizing the critical need for advanced pharmacological approaches to address these conditions. Current treatment options often focus on amplification devices, cochlear implants, or other rehabilitative therapies, leaving a substantial gap regarding effective pharmacological interventions. Advancements in our understanding of the molecular and cellular mechanisms involved in hearing disorders induced by noise, aging, and ototoxicity have opened new avenues for drug development, some of which have led to numerous clinical trials, with promising results. The development of optimal drug delivery solutions in animals and humans can also enhance the targeted delivery of medications to the ear. Moreover, large genome studies contributing to a genetic understanding of hearing loss in humans combined with advanced molecular technologies in animal studies have shown a great potential to increase our understanding of the etiologies of hearing loss. The auditory system exhibits circadian rhythms and temporal variations in its physiology, its vulnerability to auditory insults, and its responsiveness to drug treatments. The cochlear clock rhythms are under the control of the glucocorticoid system, and preclinical evidence suggests that the risk/benefit profile of hearing disorder treatments using chronopharmacological approaches would be beneficial. If translatable to the bedside, such approaches may improve the outcome of clinical trials. Ongoing research into the molecular and genetic basis of auditory disorders, coupled with advancements in drug formulation and delivery as well as optimized timing of drug administration, holds great promise of more effective treatments. SIGNIFICANCE STATEMENT: Hearing disorders pose significant challenges to individuals and their overall quality of life, emphasizing the critical need for advanced pharmacological approaches to address these conditions. Ongoing research into the molecular and genetic basis of auditory disorders, coupled with advancements in drug delivery procedures and optimized timing of drug administration, holds the promise of more effective treatments.
PURPOSE:To obtain the title compsn. which has a less skin irritating tendency, is excellent in foaming properties, and gives highly rich feeling in foam quality, by incorporating at least one N-acylamino acid salt and at least one nonionic surfactant composed of a particular alkyl glucoside. CONSTITUTION:At least one N-acylamino acid salt (A) (e.g., triethanolamine N-lauroylglutamate) and at least one nonionic surfactant (B) composed of an alkyl glucoside of the formula (wherein a is 1-15; and n is 7-19) are incorporated as essential components in an A to B wt. ratio of 0.01-100 and in such an amt. that the sum of A+B is 2-50wt.% based on the total amt. of the compsn. According to necessity, 0.1-20wt.% amphoteric surfactant (C), such as sodium 2-undecyl-N,N,N-(hydroxyethylcarboxymethyl)-2-imidazolinate, and a higher alcohol, an oil component, a water-soluble polymer, a cationic polymer, a nonionic surfactant, such as a polyoxyethylene alkyl ether, and other additives (D), are added thereto.
The invention relates to a seclenic acid I from penicillium oxalicum and application of a drug for resisting human cervical cancer. The compound has effect in inhibiting proliferation of human cervical cancer cells. The structural formula is as follows: . Culturing Penicillium oxalicum ( Penicillium oxalicum ) IBPT-6, obtaining a fermentation product, and separating and purifying the compound from the fermentation product. Experiments prove that the compound has better anti-tumor activity on human cervical cancer cells Hela. Can be used for preparing human cervical cancer cell proliferation inhibiting medicine or antitumor medicine for human cervical cancer research.
BACKGROUND: The National Surgical Quality Improvement Program (NSQIP) Surgical Risk Calculator from the American College of Surgeons is a widely available tool for peri-operative risk prediction. This study investigates its predictive performance in an Australian setting.
METHODS: A single-centre retrospective external validation study was conducted at a tertiary referral centre in New South Wales, Australia. Data from a general surgical cohort in a 2-year period from 2020 to 2021 was collected from the NSQIP database and entered into the NSQIP calculator. The predictive performance of the calculator was analysed across the standard 14 NSQIP postoperative outcome measures at 30 days.
RESULTS: There were 2121 patient records analysed using tests of accuracy and in the discrimination and calibration domains. The overall predictive performance of the NSQIP calculator was reasonable. There was greater accuracy at lower-risk predictions. At higher-risk predictions, Readmission, Death, and Discharge to Nursing or Rehab Facility, and Length of Stay were overestimated, whilst other outcomes were underestimated.
CONCLUSION: This study demonstrates reasonable overall performance of the NSQIP calculator in the context of this cohort and provides data to support the need for locally adapted and validated risk prediction tools for use by Australian perioperative physicians.
OBJECTIVE: Huntington's disease (HD) is a neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric symptoms. Our aim here was to identify factors that can be modified to slow disease progression even before the first symptoms appear.
METHODS: We included 2636 presymptomatic individuals (comparison with family controls) drawn from the prospective observational cohort Enroll-HD, with more than 35 CAG repeats and at least two assessments of disease progression measured with the composite Huntington's disease rating Scale (cUHDRS). The association between sociodemographic factors, health behaviors, health history, and cUHDRS trajectory was assessed with a mixed-effects random forest using partial dependence plots and Shapley additive explanation method.
RESULTS: Participants were followed by an average of 3.4 (SD = 1.97) years. We confirmed the negative impact of age and a high number of CAG repeats. We found that a high level of education, a body mass index (BMI) <23 kg/m2 before the age of 40 and >23 kg/m2 thereafter, alcohol consumption of <15 units per week, current coffee consumption and no smoking were linked to slow disease progression, as did no previous exposure to antidepressants or anxiolytic, no psychiatric history or comorbidities, and being female. Other comorbidities or marital status showed no major association with HD evolution.
INTERPRETATION: Reducing modifiable risk factors for HD is one way to support the presymptomatic population. A high level of education, low-to-moderate alcohol consumption, no smoking, and BMI control are likely to slow disease progression in this population.
Leptin, acting centrally or peripherally, has complex effects on cardiac remodeling and heart function. We previously reported that central leptin exerts an anti-hypertrophic effect in the heart via cardiac PPARβ/δ activation. Here, we assessed the impact of central leptin administration and PPARβ/δ inhibition on cardiac function. Various cardiac properties, including QRS duration, R wave amplitude, heart rate (HR), ejection fraction (EF), end-diastolic left ventricular mass (EDLVM), end-diastolic volume (EDV), and cardiac output (CO) were analyzed. Central leptin infusion increased cardiac PPARβ/δ protein content and decreased HR, QRS duration, and R wave amplitude. These changes induced by central leptin suggested a decrease in the ventricular wall growth, which was confirmed by MRI. In fact, the EDLVM was reduced by central leptin while increased in rats co-treated with leptin and GSK0660, a selective antagonist of PPARβ/δ activity. In summary, central leptin plays a dual role in cardiac health, potentially leading to ventricular atrophy and improving heart function when PPARβ/δ signaling is intact. The protective effects of leptin are lost by PPARβ/δ inhibition, underscoring the importance of this pathway. These findings highlight the therapeutic potential of targeting leptin and PPARβ/δ pathways to combat cardiac alterations and heart failure, particularly in the context of obesity.
Your health care professional will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health care professional believes that it is appropriate to postpone it. You should be reexamined at least once a year. Be sure to inform your health care professional if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your health care professional, because this is a time to determine if there are early signs of side effects of oral contraceptive use.

Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth-control pills.
AIMS: The aim was to evaluate whether standardised exercise performance during the incremental shuttle walk test (ISWT) can be used to assess disease severity in children and young people (CYP) with chronic conditions, through (1) identifying the most appropriate paediatric normative reference equation for the ISWT, (2) assessing how well CYP with haemophilia and cystic fibrosis (CF) perform against the values predicted by the best fit reference equation and (3) evaluating the association between standardised ISWT performance and disease severity.
METHODS: A cross-sectional analysis was carried out using existing data from two independent studies (2018-2019) at paediatric hospitals in London,UK. CYP with haemophilia (n=35) and CF (n=134) aged 5-18 years were included. Published reference equations for standardising ISWT were evaluated through a comparison of populations, and Bland-Altman analysis was used to assess the level of agreement between distances predicted by each equation. Associations between ISWT and disease severity were assessed with linear regression.
RESULTS: Three relevant reference equations were identified for the ISWT that standardised performance based on age, sex and body mass index (Vardhan, Lanza, Pinho). A systematic proportional bias of standardised ISWT was observed in all equations, most pronounced with Vardhan and Lanza; the male Pinho equation was identified as most appropriate. On average, CYP with CF and haemophilia performed worse than predicted by the Pihno equation, although the range was wide. Standardised ISWT, and not ISWT distance alone, was significantly associated with forced expiratory volume in 1 s in CYP with CF. Standardised ISWT in CYP with haemophilia was slightly associated with haemophilia joint health score, but this was not significant.
CONCLUSIONS: ISWT performance may be useful in a clinic to identify those with worsening disease, but only when performance is standardised against a healthy reference population. The development of validated global reference equations is necessary for more robust assessment.
Patent foramen ovale (PFO) is a common cardiac anomaly linked with cryptogenic strokes and migraine, particularly migraine with aura. This study aims to explore the spectrum of headache disorders in PFO patients, focusing on identifying patterns beyond the well-established migraine-PFO connection. A retrospective observational study was conducted on patients diagnosed with PFO. Headache types were classified using the International Classification of Headache Disorders, 3rd edition. The study analyzed headache prevalence and patterns in PFO patients, comparing those with and without a history of stroke. Of 177 participants, 63 (35.59%) reported headaches. Tension-type headache was the most common (15.25%), followed by migraine without aura (11.30%) and migraine with aura (8.47%). Notably, migraine without aura was more prevalent than migraine with aura, contrasting previous assumptions. No significant differences were found in headache types based on stroke history. The study reveals a diverse spectrum of headache types in PFO patients, with migraine without aura being more common than migraine with aura. These findings suggest a need for broader diagnostic perspective and individualized treatment approaches in PFO patients with headaches.
The invention discloses a Chinese patent medicine capsule for curing migraine. The Chinese patent medicine capsule is prepared from the following components according to the compatibility weight ratio of 20 g of folium ginkgo, 7 g of wild orchids and 3 g of turmeric which are prepared into 100 capsules. The three Chinese medicinal herbs, namely folium ginkgo, wild orchids and turmeric are porphyrized and uniformly stirred to be prepared into the capsule according to the compatibility weight ratio, and the capsule has a good effect on curing migraine and has small toxic and side effects. Oral use, 3 g of capsules or pills each time, three times a day, and swallow with the warm boiling water after a meal. Take 2-3 weeks repeatedly, and the capsule has a better effect to migraine. The symptoms of migraine are better alleviated, and no one case generates the toxic and side effects. After take medicine, the cases do not generate the blood pressure rebound phenomenon so far in half a year or more than one year.
Oral health is associated with overall health, especially in older adults (age 65 and older). Chronic conditions in older adults may affect oral health, and poor oral health may increase the risk of certain chronic conditions (1-3). Poor oral health has also been associated with increased cardiovascular disease risk (4). Several factors, including chronic conditions, health status, race, and income have been associated with reduced dental care use among older adults (5-9). This report describes the percentage of older adults who had a dental visit in the past 12 months by selected sociodemographic characteristics and chronic conditions using the 2022 National Health Interview Survey (NHIS). .
This trial is a proof-of-concept trial and is testing a drug to see if multiple injections to the undereye bags of selected patients decreases the volume of the eyebags as compared to placebo. Subjects will be randomized to receive either one of two doses of POLAT-001 (1 mg/mL or 2 mg/mL) or placebo (normal saline). POLAT-001 will be injected into the eyebags at three of the visits. Each subject will attend 7-10 clinic visits total over 98 to 140 days to assess efficacy and safety. Subjects assigned to placebo will crossover to receive active treatment. Efficacy will be determined using questionnaires and photography. Safety will be assessed by subject-reported events and investigator observations of the subjects.
46 patients performed a first kidney biopsy between 1992-1994. After 6 years 29 accepted to perform a second biopsy. During the follow-up 10 patients developed complications i.e. hypertension or microalbuminuria. 7 of the patients got treatment during follow up and 3 started the treatment after the second biopsy. 19 patients with two kidney biopsies were still normoalbuminuric and normotensive. 13 of them entered the double-blind treatment study of Atacand or Placebo. 6 denied to participate in the treatment study.

The treatment study will continue for 5 years and will end with a third kidney biopsy. Also the rest of the patients that have done 2 kidney biopsies will be asked to perform a third biopsy.
A method and system for in-silico testing of actives on human skin is described. The present invention discloses a micro and macroscopic level model of the skins upper protective layer Stratum-Corneum. The invention presents a multi-scale modeling framework for the calculation of diffusion and release profile of different actives like drugs, particles and cosmetics through developed skin model using molecular dynamics simulations and computational fluid dynamics approach. The systems consist of a molecular model of the skin's upper layer stratum corneum and permeate molecules. The system also consists of a macroscopic transport model of stratum corneum. The transport model is used to generate the release profile of the active molecule.
The invention relates to an application of a Radix Scutellariae extract (with the scutelloside content of 50-95%) in the pharmacy. The Radix Scutellariae extract (with the scutelloside content of 50-95%) is exploited to form medicines for treating pulmonary hypertension. A result of in vitro artery strip experiments shows that the Radix Scutellariae extract can substantially relax potassium chloride contracted pulmonary artery strips; the Radix Scutellariae extract can reduce the rat high pulmonary artery pressure caused by monocrotaline in a concentration-dependent manner; and the Radix Scutellariae extract also can inhibit the smooth muscle cell proliferation of pulmonary artery tunica media and promote the cell apoptosis. A new medical use of the known compound baicalin is excavated in the invention, and a new application field is developed. Researches find that the Radix Scutellariae extract has a very good pulmonary artery pressure reduction effect, can reduce the hypertrophy index of the right heart of the pulmonary artery high pressure rat and reverse the pulmonary artery tunica media reconstruction, and can rise the vein smooth muscle cell apoptosis associated protein Bax and decrease Bcl-2. The Radix Scutellariae extract has the advantages of nontoxic raw material, low price, low cost, safety and high efficiency.
PURPOSE:To obtain a protein absorbefacient, containing a polyamine as an active ingredient and capable of enhancing the utilization efficiency of proteins and promoting the growth of the digestive tract. CONSTITUTION:The protein absorbefacient contains a polyamine which is a straight-chain aliphatic hydrocarbon having >=2 primary amino groups, especially spermine as an active ingredient. The polyamine comprising >=20% spermine is contained in an amount of 40mug at the minimum based on 1 g proteins in the composition, especially 8mug at the minimum in the case of the spermine based on 1g proteins in the composition. The absorption of the proteins can be enhanced to keep good growth and healthy conditions by blending the polyamine therein. The load on infants in metabolism can be reduced by preparing modified milk powder for the infants having the same protein content as that of mother's milk. Furthermore, the allergy can be prevented from being induced with an ingested food by the development of the digestive tract.
Arm 1a (n=2), the pilot phase, is designed to examinethat the dosing of PYR on 2, 3 days post DVI with Sanaria PfSPZ Challenge while under CQ prophylaxis does not result in subpatent parasitemia (positive qRT-PCR result defined as two consecutive samples \> 20 parasites/uL or a single positive qRTPCR (Bullet) 100) or a single episode of patent parasitemia (positive blood smear defined as two unambiguous parasites in a thicksmear) in (Bullet)1/2 subjects. Subjects will considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).